| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
USLAB is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Partners Med B is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Cortland Acres community offers a variety of housing choices to meet the needs of active older adults.
Envisionier medical technologies Inc is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.